![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H24N4O |
Molar mass | 360.461 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug. [3] [4] [5] [6] [7] [8] It is a potent agonist for cannabinoid receptors CB1 and CB2, with in vitro EC50 values of 0.58 nM and 6.12 nM, respectively. [9] In mice, CUMYL-4CN-BINACA produces hypothermic and pro-convulsant effects via the CB1 receptor, [9] and anecdotal reports suggest it has an active dose of around 0.1 mg in humans. [10]
CUMYL-4CN-BINACA is metabolized to produce cyanide, raising concerns about liver toxicity. [8] There is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with its use. [11]